Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.

Hézode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R, Robertson MN, Haber BA.

Int J Womens Health. 2019 Nov 20;11:617-628. doi: 10.2147/IJWH.S203022. eCollection 2019.

2.

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus: genotype 4 infection: a randomized study.

Asselah T, Pol S, Hezode C, Loustaud-Ratti V, Leroy V, Ahmed SNS, Ozenne V, Bronowicki JP, Larrey D, Tran A, Alric L, Nguyen-Khac E, Robertson MN, Hanna GJ, Brown D, Asante-Appiah E, Su FH, Hwang P, Hall JD, Guidoum A, Hagen K, Haber BA, Talwani R, Serfaty L.

Liver Int. 2019 Nov 25. doi: 10.1111/liv.14313. [Epub ahead of print]

PMID:
31765046
3.

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older.

Flamm S, Peng CY, Shibolet O, Nahass R, Hwang P, Barr E, Robertson MN, Haber BA.

Gerontol Geriatr Med. 2019 Jan 22;5:2333721418817398. doi: 10.1177/2333721418817398. eCollection 2019 Jan-Dec.

4.

Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.

Wei L, Kumada H, Perumalswami PV, Tanwandee T, Cheng W, Heo J, Cheng PN, Hwang P, Mu SM, Zhao XM, Asante-Appiah E, Caro L, Hanna GJ, Robertson MN, Haber BA, Talwani R.

J Gastroenterol Hepatol. 2019 Sep;34(9):1597-1603. doi: 10.1111/jgh.14636. Epub 2019 Apr 17.

PMID:
30779220
5.

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.

Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng CY, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, Haber BA.

Gastroenterology. 2017 May;152(6):1372-1382.e2. doi: 10.1053/j.gastro.2017.01.050. Epub 2017 Feb 11.

6.

The inflammatory phenotype of the fibrous plate is distinct from the liver and correlates with clinical outcome in biliary atresia.

Arva NC, Russo PA, Erlichman J, Hancock WW, Haber BA, Bhatti TR.

Pathol Res Pract. 2015 Mar;211(3):252-60. doi: 10.1016/j.prp.2014.12.003. Epub 2015 Jan 6.

PMID:
25624184
7.

Maternal-fetal transmission of hepatitis C infection: what is so special about babies?

Wen JW, Haber BA.

J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):278-82. doi: 10.1097/MPG.0000000000000258. Review.

PMID:
24345835
8.

Replication of a GWAS signal in a Caucasian population implicates ADD3 in susceptibility to biliary atresia.

Tsai EA, Grochowski CM, Loomes KM, Bessho K, Hakonarson H, Bezerra JA, Russo PA, Haber BA, Spinner NB, Devoto M.

Hum Genet. 2014 Feb;133(2):235-43. doi: 10.1007/s00439-013-1368-2. Epub 2013 Oct 9.

9.

Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.

Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):304-10. doi: 10.1097/MPG.0b013e3182774cae.

10.

Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene.

Cui S, Leyva-Vega M, Tsai EA, EauClaire SF, Glessner JT, Hakonarson H, Devoto M, Haber BA, Spinner NB, Matthews RP.

Gastroenterology. 2013 May;144(5):1107-1115.e3. doi: 10.1053/j.gastro.2013.01.022. Epub 2013 Jan 18.

11.

Intrahepatic biliary anomalies in a patient with Mowat-Wilson syndrome uncover a role for the zinc finger homeobox gene zfhx1b in vertebrate biliary development.

Cui S, Erlichman J, Russo P, Haber BA, Matthews RP.

J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):339-44. doi: 10.1097/MPG.0b013e3181ff2e5b.

PMID:
21336163
12.

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network.

Gastroenterology. 2011 Feb;140(2):450-458.e1. doi: 10.1053/j.gastro.2010.10.047. Epub 2010 Oct 28.

13.

Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.

Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ; Hepatitis B Foundation.

Hepatology. 2010 Dec;52(6):2192-205. doi: 10.1002/hep.23934. Epub 2010 Oct 1.

PMID:
20890947
14.

Genomic alterations in biliary atresia suggest region of potential disease susceptibility in 2q37.3.

Leyva-Vega M, Gerfen J, Thiel BD, Jurkiewicz D, Rand EB, Pawlowska J, Kaminska D, Russo P, Gai X, Krantz ID, Kamath BM, Hakonarson H, Haber BA, Spinner NB.

Am J Med Genet A. 2010 Apr;152A(4):886-95. doi: 10.1002/ajmg.a.33332.

15.

Use of complementary and alternative medicine in pediatric chronic viral hepatitis.

Erlichman J, Salam A, Haber BA.

J Pediatr Gastroenterol Nutr. 2010 Apr;50(4):417-21. doi: 10.1097/MPG.0b013e3181b99cba.

PMID:
20179638
16.

Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B.

Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB; Hepatitis B Foundation.

Pediatrics. 2009 Nov;124(5):e1007-13. doi: 10.1542/peds.2009-0567. Epub 2009 Oct 5.

PMID:
19805457
17.

Biliary atresia: how medical complications and therapies impact outcome.

Erlichman J, Hohlweg K, Haber BA.

Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):425-34. doi: 10.1586/egh.09.30. Review.

PMID:
19673629
18.

Bone health in a nonjaundiced population of children with biliary atresia.

Kramer RA, Zemel BS, Arvay-Nezu JL, Stallings VA, Leonard MB, Haber BA.

Gastroenterol Res Pract. 2009;2009:387029. doi: 10.1155/2009/387029. Epub 2009 Jul 5.

19.

Recent advances in biliary atresia: prospects for novel therapies.

Haber BA, Erlichman J, Loomes KM.

Expert Opin Investig Drugs. 2008 Dec;17(12):1911-24. doi: 10.1517/13543780802514120 . Review.

PMID:
19012506
20.

Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium.

DeRusso PA, Ye W, Shepherd R, Haber BA, Shneider BL, Whitington PF, Schwarz KB, Bezerra JA, Rosenthal P, Karpen S, Squires RH, Magee JC, Robuck PR, Sokol RJ; Biliary Atresia Research Consortium.

Hepatology. 2007 Nov;46(5):1632-8.

21.

Successful revision of portoenterostomy in an infant with biliary atresia.

Haber BA, Erlichman J, Thayu M, Flake AW, Rand EB.

J Pediatr Surg. 2006 Jul;41(7):e1-3.

PMID:
16818040
22.

Does "cystic" biliary atresia represent a distinct clinical and etiological subgroup? A series of three cases.

De Matos V, Erlichman J, Russo PA, Haber BA.

Pediatr Dev Pathol. 2005 Nov-Dec;8(6):725-31. Epub 2005 Nov 18.

PMID:
16328669
23.

Body composition of children aged 1 to 12 years with biliary atresia or Alagille syndrome.

Arvay JL, Zemel BS, Gallagher PR, Rovner AJ, Mulberg AE, Stallings VA, Haber BA.

J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):146-50.

PMID:
15699687
24.
25.

To treat or not to treat: that is the question.

Haber BA.

J Pediatr Gastroenterol Nutr. 2004 Jul;39(1):103-4. No abstract available.

PMID:
15187792
26.

Biliary atresia.

Haber BA, Russo P.

Gastroenterol Clin North Am. 2003 Sep;32(3):891-911. Review.

PMID:
14562580
27.

Hepatic jagged1 expression studies.

Louis AA, Van Eyken P, Haber BA, Hicks C, Weinmaster G, Taub R, Rand EB.

Hepatology. 1999 Nov;30(5):1269-75.

PMID:
10534349
28.

Sepsis-induced depression of rat glucose-6-phosphatase gene expression and activity.

Deutschman CS, Andrejko KM, Haber BA, Bellin L, Elenko E, Harrison R, Taub R.

Am J Physiol. 1997 Nov;273(5):R1709-18. doi: 10.1152/ajpregu.1997.273.5.R1709.

PMID:
9374814
29.
30.

Increased expression of cytokine-induced neutrophil chemoattractant in septic rat liver.

Deutschman CS, Haber BA, Andrejko K, Cressman DE, Harrison R, Elenko E, Taub R.

Am J Physiol. 1996 Sep;271(3 Pt 2):R593-600.

PMID:
8853380
31.

Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine.

Diamond RH, Peters C, Jung SP, Greenbaum LE, Haber BA, Silberg DG, Traber PG, Taub R.

Am J Physiol. 1996 Jul;271(1 Pt 1):G121-9.

PMID:
8760115
32.

Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia.

Haber BA, Chuang E, Lee W, Taub R.

Hepatology. 1996 Jul;24(1):65-71.

PMID:
8707285
34.

High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes.

Haber BA, Chin S, Chuang E, Buikhuisen W, Naji A, Taub R.

J Clin Invest. 1995 Feb;95(2):832-41.

35.
36.

Structure and localization of the IGFBP-1 gene and its expression during liver regeneration.

Lee J, Greenbaum L, Haber BA, Nagle D, Lee V, Miles V, Mohn KL, Bucan M, Taub R.

Hepatology. 1994 Mar;19(3):656-65.

PMID:
7509771
37.

Novel delayed-early and highly insulin-induced growth response genes. Identification of HRS, a potential regulator of alternative pre-mRNA splicing.

Diamond RH, Du K, Lee VM, Mohn KL, Haber BA, Tewari DS, Taub R.

J Biol Chem. 1993 Jul 15;268(20):15185-92.

38.
39.

Hepatitis C virus infection in infants whose mothers took illicit drugs intravenously.

Haber BA, Maller ES, Watkins JB.

J Pediatr. 1991 Dec;119(6):929-31. No abstract available.

PMID:
1960608
40.

Cholestatic jaundice in the newborn.

Haber BA, Lake AM.

Clin Perinatol. 1990 Jun;17(2):483-506. Review.

PMID:
2196142

Supplemental Content

Loading ...
Support Center